Duality Advisers LP Reduces Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Duality Advisers LP reduced its holdings in Hologic, Inc. (NASDAQ:HOLX) by 78.2% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 17,305 shares of the medical equipment provider’s stock after selling 62,100 shares during the period. Duality Advisers LP’s holdings in Hologic were worth $1,349,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. McGlone Suttner Wealth Management Inc. bought a new stake in Hologic during the 4th quarter valued at about $27,000. Massmutual Trust Co. FSB ADV raised its holdings in shares of Hologic by 69.4% in the 4th quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock valued at $40,000 after purchasing an additional 227 shares in the last quarter. Allworth Financial LP raised its holdings in shares of Hologic by 39.3% in the 4th quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 179 shares in the last quarter. Mather Group LLC. bought a new stake in shares of Hologic in the 1st quarter valued at about $48,000. Finally, Livforsakringsbolaget Skandia Omsesidigt grew its position in shares of Hologic by 145.3% in the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 790 shares of the medical equipment provider’s stock worth $56,000 after buying an additional 468 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on HOLX. Argus lifted their price objective on shares of Hologic from $89.00 to $95.00 and gave the stock a “buy” rating in a research report on Thursday, May 9th. Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and increased their price target for the stock from $80.00 to $95.00 in a report on Wednesday, April 3rd. Needham & Company LLC reissued a “buy” rating and set a $90.00 price target on shares of Hologic in a report on Friday, May 3rd. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. Finally, Stephens initiated coverage on shares of Hologic in a report on Thursday, June 27th. They set an “overweight” rating and a $87.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $85.55.

Hologic Price Performance

Shares of NASDAQ HOLX traded up $1.40 during mid-day trading on Friday, reaching $77.89. The company’s stock had a trading volume of 862,580 shares, compared to its average volume of 1,613,683. Hologic, Inc. has a 1-year low of $64.02 and a 1-year high of $82.45. The stock has a market capitalization of $18.18 billion, a P/E ratio of 39.08, a P/E/G ratio of 2.52 and a beta of 0.99. The stock has a 50-day moving average of $74.00 and a two-hundred day moving average of $74.50. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.29 and a current ratio of 3.97.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.05. Hologic had a net margin of 11.78% and a return on equity of 18.91%. The firm had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. During the same period last year, the business earned $1.06 earnings per share. Hologic’s revenue was down .8% compared to the same quarter last year. On average, equities research analysts anticipate that Hologic, Inc. will post 4.08 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.